Business Wire

CA-VISA

21.12.2021 12:02:09 CET | Business Wire | Press release

Share
Visa Expands Global Investment in Women’s Football as First Ever FIFA Women’s Football Partner

Visa (NYSE:V) today announced it has further expanded its support of women’s football by becoming the first Women’s Football Partner for the FIFA Women’s World Cup 2023™. This investment builds on long-term commitments Visa has made across Europe and around the world, to help elevate women’s football and usher in greater equality within the sport.

“Women are a force to be reckoned with – on the pitch, as small business owners, and as drivers of a majority of consumer purchases. We know that when we support the success of women in sport, we support the success of women everywhere,” said Lynne Biggar, Chief Marketing Officer, Visa. “Becoming the first FIFA Women’s Football Partner is part of a much larger investment in women’s initiatives to help recognize the limitless potential of women around the world.”

Visa is one of the world’s most active sponsors of women’s football. Through the company’s sponsorship of the FIFA Women's World Cup 2023™ and other leading women’s football organizations around the world, the company strives to be a catalyst for change and contribute to the growing recognition of women’s football. The FIFA Women's World Cup 2019™ tournament was watched by a record 1.12 billion viewers1 and marked Visa’s largest onsite investment in women’s football, providing the latest payment technology at all venues and curating exclusive experiences for consumers and clients from around the world.

As the FIFA Women’s World Cup™ heads to Australia and New Zealand in 2023, marking the first time the Tournament will be played across two countries and be expanded to 32 teams, Visa will enable similar one-of-a-kind experiences for football fans globally, activate the Player of the Match award and incorporate its Team Visa program for women footballers. Additionally, as the Exclusive Payment Service for the FIFA Women’s World Cup 2023™, Visa will implement its innovative payment technology at tournament venues and deliver exclusive experiences for fans and clients, ranging from delivering innovative ways to pay to utilizing Visa’s exclusive marketing campaign assets to drive mutual business priorities with clients.

“As a long-standing FIFA Partner and a proud supporter of women’s football, it was a natural choice for Visa to become the first ever Women’s Football Partner at FIFA,” said Sarai Bareman, FIFA’s Chief Women’s Football Officer. “Visa is well known for supporting athletes and seeing the positive benefits that can come through sport. They are advocates for equality, diversity, and inclusion, core values that are shared by FIFA and the FIFA Women’s World Cup, as we grow and celebrate the women’s game.”

Given the correlation between success in sport and business – 94% of women in the C-suite have played a sport at some time in their lives2 – Visa’s support for women does not end on the pitch. Visa continues to develop programs that open more opportunities for women on and off the field:

  • Team Visa: Designed to help athletes succeed in their athletic career and beyond, Team Visa has championed more than 500 athletes since its inception. Of those athletes, 55% are women, including 22 female footballers such as Lucy Bronze (England), Alexia Putellas (Spain) and Ellie Carpenter (Australia).
  • The Second Half: Launched in the UK in early 2021, the Second Half is a Visa career development program to support female footballers as they consider careers beyond football. The program helps women recognize how to translate the skills they have developed – perseverance, teamwork, and commitment – outside of sport.
  • She’s Next, Empowered by Visa: Broader Visa programs – such as She’s Next – support women entrepreneurs around the world and work to close gaps with educational tools, mentorship and meaningful funding.

“I love having the opportunity to encourage young people to chase their dreams and am so proud to be part of Team Visa because the company shares this same vision and supports what I do,” said Ellie Carpenter, defender on Australia’s national women’s football team. “To be looking ahead toward playing the FIFA Women’s World Cup 2023™ in my home country is an absolute dream come true.”

Visa’s first-ever sponsorship of the FIFA Women’s World Cup 2023™ complements its global investment in women’s football , including its ground-breaking partnership with UEFA Women’s Football, and sponsorship of the U.S. Soccer Federation, including the U.S. Women’s National Team and the SheBelieves Cup. It also builds on Visa’s longstanding partnership with FIFA, including the FIFA World Cup™, FIFA Women's World Cup™ and other FIFA events.

About Visa Inc.
Visa (NYSE: V) is a world leader in digital payments, facilitating more than 215 billion payments transactions between consumers, merchants, financial institutions and government entities across more than 200 countries and territories each year. Our mission is to connect the world through the most innovative, convenient, reliable and secure payments network, enabling individuals, businesses and economies to thrive. We believe that economies that include everyone everywhere, uplift everyone everywhere and see access as foundational to the future of money movement. Learn more at Visa.com .

____________________
1 FIFA , October 2019
2 EY, “Why a Female Athlete Should Be Your Next Leader” , September 2020

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye